Comparative Evaluation of the Safety and Efficacy of Botulinum Toxin Type A and Topical Creams for Treating Moderate‐to‐Severe Glabellar Rhytids
BACKGROUND Several nonprescription products purport similar or better outcomes than botulinum toxin type A (Botox® Cosmetic) for treating wrinkles, but these have not been documented in comparative clinical trials. Patients spend millions of dollars annually on the topical products, yet there are, t...
Gespeichert in:
| Veröffentlicht in: | Dermatologic surgery 2006-02, Vol.32 (2), p.184-192 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 192 |
|---|---|
| container_issue | 2 |
| container_start_page | 184 |
| container_title | Dermatologic surgery |
| container_volume | 32 |
| creator | BEER, KENNETH R. |
| description | BACKGROUND
Several nonprescription products purport similar or better outcomes than botulinum toxin type A (Botox® Cosmetic) for treating wrinkles, but these have not been documented in comparative clinical trials. Patients spend millions of dollars annually on the topical products, yet there are, to date, no data to support any of the claims made.
OBJECTIVE
To compare the efficacy and safety of botulinum toxin type A to placebo and three topical products in treating moderate‐to‐severe glabellar lines.
METHODS
This single‐center, randomized, investigator‐blinded, parallel study of 77 female subjects comprised five treatment groups: botulinum toxin type A, placebo injection, StriVectin‐SD®, Wrinkle Relax™, and HydroDerm™. Baseline and follow‐up visits (weeks 4, 8, and 12) assessed safety and key efficacy measures: blinded investigator assessment of glabellar line severity on the Facial Wrinkle Scale (FWS); subjects' global assessment of overall change in appearance; subject ratings of glabellar‐related self‐perception pre‐ and post‐treatment and satisfaction with treatment.
RESULTS
Botulinum toxin type A treatment consistently resulted in statistically significant reductions in wrinkle severity on the FWS than any comparator (p |
| doi_str_mv | 10.1111/j.1524-4725.2006.32036.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_wiley</sourceid><recordid>TN_cdi_proquest_miscellaneous_19847008</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19847008</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2116-ce5a14ed839b584760740c5b8a113eac13c7dc320754266f7df13b49721b39623</originalsourceid><addsrcrecordid>eNo9UctOwzAQjBBIlMI_-MQtwY88L0gllIJUhETTs-U4G-oqiUMepbnxCRz4Qr4Ep0XsYXekGe2uZiwLEewQUzdbh3jUtd2Aeg7F2HcYxcx39ifW5J84NRgHvo09Qs-ti7bdYkxoxPDE-o51WYtGdGoHaL4TRW-grpDOUbcBtBI5dAMSVYbmea6kkMNI3emuL1TVlyjRe1WhZKgBzQ6yRNdGVqC4AVG2KNcNSgzsVPWGnnUG5hT8fH512rQV7KABtChECkUhGvS6GTqVtZfWWS6KFq7-5tRaP8yT-NFeviye4tnSlpQQ35bgCeJCFrIo9UI38HHgYumloSCEgZCEySCTxo_Ac6nv50GWE5a6UUBJyiKfsql1fdxbN_q9h7bjpWrl-EoFum85icxWjEMjvD0KP1QBA68bVYpm4ATzMQO-5aPVfLSajxnwQwZ8z-9X6wNkv5YXgA8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19847008</pqid></control><display><type>article</type><title>Comparative Evaluation of the Safety and Efficacy of Botulinum Toxin Type A and Topical Creams for Treating Moderate‐to‐Severe Glabellar Rhytids</title><source>Wiley Online Library Journals Frontfile Complete</source><source>Journals@Ovid Complete</source><creator>BEER, KENNETH R.</creator><creatorcontrib>BEER, KENNETH R.</creatorcontrib><description>BACKGROUND
Several nonprescription products purport similar or better outcomes than botulinum toxin type A (Botox® Cosmetic) for treating wrinkles, but these have not been documented in comparative clinical trials. Patients spend millions of dollars annually on the topical products, yet there are, to date, no data to support any of the claims made.
OBJECTIVE
To compare the efficacy and safety of botulinum toxin type A to placebo and three topical products in treating moderate‐to‐severe glabellar lines.
METHODS
This single‐center, randomized, investigator‐blinded, parallel study of 77 female subjects comprised five treatment groups: botulinum toxin type A, placebo injection, StriVectin‐SD®, Wrinkle Relax™, and HydroDerm™. Baseline and follow‐up visits (weeks 4, 8, and 12) assessed safety and key efficacy measures: blinded investigator assessment of glabellar line severity on the Facial Wrinkle Scale (FWS); subjects' global assessment of overall change in appearance; subject ratings of glabellar‐related self‐perception pre‐ and post‐treatment and satisfaction with treatment.
RESULTS
Botulinum toxin type A treatment consistently resulted in statistically significant reductions in wrinkle severity on the FWS than any comparator (p<.001). Statistically significant improvements were similarly observed for subject‐reported outcomes and satisfaction with botulinum toxin type A treatment, whereas treatment with any of the three topical creams did not result in a significant difference from placebo. Three adverse events occurred in three subjects who received StriVectin‐SD.
CONCLUSION
Botulinum toxin type A provided significantly greater efficacy and patient satisfaction in the treatment of glabellar frown lines than StriVectin‐SD, Wrinkle Relax, and HydroDerm, and in the objective measurements utilized, none of the topical preparations were better than Botox.</description><identifier>ISSN: 1076-0512</identifier><identifier>EISSN: 1524-4725</identifier><identifier>DOI: 10.1111/j.1524-4725.2006.32036.x</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><ispartof>Dermatologic surgery, 2006-02, Vol.32 (2), p.184-192</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2116-ce5a14ed839b584760740c5b8a113eac13c7dc320754266f7df13b49721b39623</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1524-4725.2006.32036.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1524-4725.2006.32036.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids></links><search><creatorcontrib>BEER, KENNETH R.</creatorcontrib><title>Comparative Evaluation of the Safety and Efficacy of Botulinum Toxin Type A and Topical Creams for Treating Moderate‐to‐Severe Glabellar Rhytids</title><title>Dermatologic surgery</title><description>BACKGROUND
Several nonprescription products purport similar or better outcomes than botulinum toxin type A (Botox® Cosmetic) for treating wrinkles, but these have not been documented in comparative clinical trials. Patients spend millions of dollars annually on the topical products, yet there are, to date, no data to support any of the claims made.
OBJECTIVE
To compare the efficacy and safety of botulinum toxin type A to placebo and three topical products in treating moderate‐to‐severe glabellar lines.
METHODS
This single‐center, randomized, investigator‐blinded, parallel study of 77 female subjects comprised five treatment groups: botulinum toxin type A, placebo injection, StriVectin‐SD®, Wrinkle Relax™, and HydroDerm™. Baseline and follow‐up visits (weeks 4, 8, and 12) assessed safety and key efficacy measures: blinded investigator assessment of glabellar line severity on the Facial Wrinkle Scale (FWS); subjects' global assessment of overall change in appearance; subject ratings of glabellar‐related self‐perception pre‐ and post‐treatment and satisfaction with treatment.
RESULTS
Botulinum toxin type A treatment consistently resulted in statistically significant reductions in wrinkle severity on the FWS than any comparator (p<.001). Statistically significant improvements were similarly observed for subject‐reported outcomes and satisfaction with botulinum toxin type A treatment, whereas treatment with any of the three topical creams did not result in a significant difference from placebo. Three adverse events occurred in three subjects who received StriVectin‐SD.
CONCLUSION
Botulinum toxin type A provided significantly greater efficacy and patient satisfaction in the treatment of glabellar frown lines than StriVectin‐SD, Wrinkle Relax, and HydroDerm, and in the objective measurements utilized, none of the topical preparations were better than Botox.</description><issn>1076-0512</issn><issn>1524-4725</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNo9UctOwzAQjBBIlMI_-MQtwY88L0gllIJUhETTs-U4G-oqiUMepbnxCRz4Qr4Ep0XsYXekGe2uZiwLEewQUzdbh3jUtd2Aeg7F2HcYxcx39ifW5J84NRgHvo09Qs-ti7bdYkxoxPDE-o51WYtGdGoHaL4TRW-grpDOUbcBtBI5dAMSVYbmea6kkMNI3emuL1TVlyjRe1WhZKgBzQ6yRNdGVqC4AVG2KNcNSgzsVPWGnnUG5hT8fH512rQV7KABtChECkUhGvS6GTqVtZfWWS6KFq7-5tRaP8yT-NFeviye4tnSlpQQ35bgCeJCFrIo9UI38HHgYumloSCEgZCEySCTxo_Ac6nv50GWE5a6UUBJyiKfsql1fdxbN_q9h7bjpWrl-EoFum85icxWjEMjvD0KP1QBA68bVYpm4ATzMQO-5aPVfLSajxnwQwZ8z-9X6wNkv5YXgA8</recordid><startdate>200602</startdate><enddate>200602</enddate><creator>BEER, KENNETH R.</creator><general>Blackwell Publishing Inc</general><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>200602</creationdate><title>Comparative Evaluation of the Safety and Efficacy of Botulinum Toxin Type A and Topical Creams for Treating Moderate‐to‐Severe Glabellar Rhytids</title><author>BEER, KENNETH R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2116-ce5a14ed839b584760740c5b8a113eac13c7dc320754266f7df13b49721b39623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BEER, KENNETH R.</creatorcontrib><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Dermatologic surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BEER, KENNETH R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative Evaluation of the Safety and Efficacy of Botulinum Toxin Type A and Topical Creams for Treating Moderate‐to‐Severe Glabellar Rhytids</atitle><jtitle>Dermatologic surgery</jtitle><date>2006-02</date><risdate>2006</risdate><volume>32</volume><issue>2</issue><spage>184</spage><epage>192</epage><pages>184-192</pages><issn>1076-0512</issn><eissn>1524-4725</eissn><abstract>BACKGROUND
Several nonprescription products purport similar or better outcomes than botulinum toxin type A (Botox® Cosmetic) for treating wrinkles, but these have not been documented in comparative clinical trials. Patients spend millions of dollars annually on the topical products, yet there are, to date, no data to support any of the claims made.
OBJECTIVE
To compare the efficacy and safety of botulinum toxin type A to placebo and three topical products in treating moderate‐to‐severe glabellar lines.
METHODS
This single‐center, randomized, investigator‐blinded, parallel study of 77 female subjects comprised five treatment groups: botulinum toxin type A, placebo injection, StriVectin‐SD®, Wrinkle Relax™, and HydroDerm™. Baseline and follow‐up visits (weeks 4, 8, and 12) assessed safety and key efficacy measures: blinded investigator assessment of glabellar line severity on the Facial Wrinkle Scale (FWS); subjects' global assessment of overall change in appearance; subject ratings of glabellar‐related self‐perception pre‐ and post‐treatment and satisfaction with treatment.
RESULTS
Botulinum toxin type A treatment consistently resulted in statistically significant reductions in wrinkle severity on the FWS than any comparator (p<.001). Statistically significant improvements were similarly observed for subject‐reported outcomes and satisfaction with botulinum toxin type A treatment, whereas treatment with any of the three topical creams did not result in a significant difference from placebo. Three adverse events occurred in three subjects who received StriVectin‐SD.
CONCLUSION
Botulinum toxin type A provided significantly greater efficacy and patient satisfaction in the treatment of glabellar frown lines than StriVectin‐SD, Wrinkle Relax, and HydroDerm, and in the objective measurements utilized, none of the topical preparations were better than Botox.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><doi>10.1111/j.1524-4725.2006.32036.x</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1076-0512 |
| ispartof | Dermatologic surgery, 2006-02, Vol.32 (2), p.184-192 |
| issn | 1076-0512 1524-4725 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_19847008 |
| source | Wiley Online Library Journals Frontfile Complete; Journals@Ovid Complete |
| title | Comparative Evaluation of the Safety and Efficacy of Botulinum Toxin Type A and Topical Creams for Treating Moderate‐to‐Severe Glabellar Rhytids |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T02%3A53%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_wiley&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20Evaluation%20of%20the%20Safety%20and%20Efficacy%20of%20Botulinum%20Toxin%20Type%20A%20and%20Topical%20Creams%20for%20Treating%20Moderate%E2%80%90to%E2%80%90Severe%20Glabellar%20Rhytids&rft.jtitle=Dermatologic%20surgery&rft.au=BEER,%20KENNETH%20R.&rft.date=2006-02&rft.volume=32&rft.issue=2&rft.spage=184&rft.epage=192&rft.pages=184-192&rft.issn=1076-0512&rft.eissn=1524-4725&rft_id=info:doi/10.1111/j.1524-4725.2006.32036.x&rft_dat=%3Cproquest_wiley%3E19847008%3C/proquest_wiley%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19847008&rft_id=info:pmid/&rfr_iscdi=true |